Full-Time

Field Reimbursement Manager

Rare Disease

Posted on 9/23/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$150k - $185k/yr

+ Sales Incentive

Boston, MA, USA

In Person

Ideal candidates would like near a major airport.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Bachelor’s Degree or equivalent experience required
  • A minimum of 5+ years of experience in a Market Access and/or Patient Services role, with extensive prior knowledge in patient access and reimbursement required
  • Proficient in MS Office Suite
Responsibilities
  • Provide coordination of care to patients and their caregivers accessing a rare disease product by working with Healthcare Providers to ensure access
  • In person meetings with patients, healthcare providers, and/or other office staff to discuss and educate on product specific coverage and reimbursement, alternative insurance and coverage options, and relevant information to aid in the continued access of a rare disease product.
  • Assist with and provide information and education regarding general reimbursement and process related information and assistance to help HCPs obtain reimbursement for their patients
  • Ensure that all patients and providers are well educated and informed throughout the treatment journey to ensure and maintain treatment schedule as prescribed by their provider
  • Subject matter expert on relevant reimbursement topics related to rare disease therapy
  • Billing, reimbursement, and procurement options expert
  • Able to provide support to help troubleshoot billing and coverage hurdles with office staff
  • Provide ongoing support and input to Kyowa Kirin’s Patient Services, Marketing, Market Access, Sales, Legal/Compliance, and Medical team partners as needed in order to provide on-going support
  • Liaison with Kyowa Kirin’s Commercial team’s internal and external stakeholders
  • Attend meetings and represent Kyowa Kirin at industry conferences as needed
  • Attendance at company sponsored and external customer meetings when requested
  • Expertise in regionally based plan/policy as well as nationally and government funded plans
  • Understanding of company based and external alternative co-pay and financial support programs, 501c3 and other advocacy groups
Desired Qualifications
  • 3+ years informal leadership experience in biotech/pharmaceutical industry required, product launch experience a plus
  • Rare Disease and Specialty products experience preferred
  • Ability to speak Spanish Preferred
  • Highly Patient Focused
  • Exceptional enthusiasm with a drive to succeed
  • Demonstrated track record of professional growth
  • Ability to strategically think and tactically execute on patient and departmental objectives
  • Ability to collaborate, educate and lead peers all while working cohesively within a team environment, both office and field based
  • Ability to assist with providing information regarding complex reimbursement and processes to patients and their medical professionals
  • Remain professional during interactions with all patients, families, and other medical professionals
  • Excellent organizational, written, listening, and communication skills a must
  • Excellent time management skills, both team and individually
  • Ability to influence others without authority
  • Understanding of specialty channel patient-level data
  • Quick learner and ability to adapt to change

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE